Words Matter: How the Universal Definition of Heart Failure Will Influence Research

SCOTT D. SOLOMON, O. R.L.Y. VARDENY

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)1042-1044
Number of pages3
JournalJournal of cardiac failure
Volume27
Issue number10
Early online dateAug 30 2021
DOIs
StatePublished - Oct 1 2021

Bibliographical note

Funding Information:
Disclosures: Dr. Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, US2. AI and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boeringer-Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta Dr. Vardeny has received research grants from NIH/NHLBI, FDA, AstraZeneca, Bayer, and has consulted for Bayer, Novartis, and Sanofi-Pasteur.

Cite this